Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term omalizumab extension in Japanese children (CIGE025B1301 extension)
jRCT2080221414Phase 3
- Sponsor
- Novartis
- Start
- Mar 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of omalizumab in allergic asthma, sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of omalizumab.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on jRCT2080221414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221414.